Manufacturing Part Of GSK Proposal For Single Dose Antimalarial In India
GlaxoSmithKline has proposed to market and manufacture antimalarial Krintafel in India and an expert panel has sought additional information to progress a review of these plans. GSK and partner MMV aim to ensure that the cost of the therapy does not impede access.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Approval could bring GlaxoSmithKline a tropical disease priority review voucher.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.